Skip to main content
Fig. 7 | Antimicrobial Resistance & Infection Control

Fig. 7

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 7

One-way deterministic sensitivity analysis for CAZ-AVI sequence vs. meropenem sequence, INB based on a willingness-to-pay threshold, Abbreviations: CAZ-AVI ceftazidime-avibactam, cIAI complicated intra-abdominal infection, EOT end-of-treatment, INB incremental net benefit, Prob probability, TOC test-of-cure. CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Meropenem sequence: Meropenem, followed by colistin + tigecycline + high-dose meropenem.

Note: Positive INB indicates CAZ-AVI sequence was cost effective compared to meropenem sequence, and vice versa

Back to article page